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Summary The distribution among the main fractions of human plasma lipoproteins of a number of
porphyrins with different tumour localising ability has been determined by means of ultracentrifugation. A
main trend is that the fraction of the dyes that are bound to low density lipoprotein (LDL) increases, and the
fraction bound to HSA decreases with decreasing polarity of the dyes. An asymmetric charge distribution,
such as in TPPS2a, favours LDL-binding more than expected on the basis of lipophilicity. No correlation
between the known tumour localising ability of the drugs tested in the present work and their relative affinity
for LDL was found. One of the best tumour localisers reported in the literature, TPPS4, hardly binds to
LDL, while Hp and Pp, which are commonly considered inefficient tumour localisers, do have a significant
affinity for LDL. On the other hand, the LDL binding capacity for a drug is suggested to be a good index for
cellular uptake. Such an index does not necessarily imply that the actual uptake occurs by the LDL pathway.
Subsequent to studies describing porphyrin binding to
plasma lipoproteins (Jori et al., 1984; Reyftman et al., 1984;
Moan et al., 1985), including the observation that
lipoproteins play an important role in the transport of
haematoporphyrin (Hp) in the bloodstream (Jori et al.,
1984), it has been suggested that the tumour localising
property of the porphyrin photosensitisers used in photo-
dynamic therapy (PDT) is related to such binding,
particularly to low density lipoprotein (LDL) (Reyftman et
al., 1984; Barel et al., 1986; Kessel, 1986; Kessel et al., 1987).
The possibility of delivering various kinds of cytotoxic,
antitumoral and/or photosensitising drugs via the receptor-
mediated pathway of LDL has received much attention
because various types of cancer cells have considerably
higher LDL receptor activity than the corresponding normal
cells (e.g. Norata et al., 1984; Vitols et al., 1985; Gal et al.,
1981; Iwanik et al., 1984). Such enhanced LDL activity is
supposedly due to the high requirement for cholesterol in
rapidly proliferating cells, LDL being the major extracellular
vehicle for the transport of cholesterol to extrahepatic
animal and human cells (Brown et al., 1981).
Following administration of haematoporphyrin derivatives
(HpD) to patients (D.I. Vernon, unpublished) or to
experimental animals, the major tumour localising fraction
preferentially binds to LDL and HDL (Kessel, 1986). This
fraction of HpD was not detected at all in high performance
liquid chromatography (HPLC) analysis of the albumin
fraction of the mouse plasma, neither 0.5 h nor 48 h after the
administration of HpD. The binding of Hp and HpD to
lipoproteins may influence their distribution in different
tissues. Thus, administration to tumour-bearing mice of in
vitro prepared complexes of Hp and LDL appears to deliver
substantially more Hp to the mouse tumour (MS-2
fibrosarcoma) than does administration of Hp-complexes of
very low density lipoproteins (VLDL), high density
lipoproteins (HDL) or free Hp (Barel et al., 1986).
In the present work we have studied the pattern of
distribution among human plasma proteins of a range of
porphyrin photosensitisers relevant to PDT. These
compounds vary significantly, both with respect to
lipophilicity and, in certain cases, their known uptake and
tumour selectivity. (The latter two terms are here defined as
by Peng et al. (1987).) Our objectives were to find out if
there is any correlation between the lipophilicity (determined
by HPLC-retention times) and the LDL-binding capacity for
these drugs and to discuss whether such capacity may be a
main determinant for tumour localisation.
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It has been reported that some PDT sensitisers are cleared
more rapidly from LDL than from HDL in mice, implying
that there is no equilibrium redistribution (Barel et al., 1986;
Kessel, 1986). We have checked if this can be explained by a
slow redistribution of drugs among the different plasma
proteins.
Materials and methods
Materials
Hp, protoporphyrin (Pp) and photoprotoporphyrin (Ppp)
were bought from Porphyrin Products (Logan, UT, USA).
PhotofrinII (PII) (2.5 mgml -1) was obtained from
Photomedica (Raritan, NJ, USA) and stored frozen in small
vials. The tetraphenyl porphine sulphonates (TPPSI,) were
kind gifts from Dr Bruce Burnham at Porphyrin Products.
These sulphonated porphyrins belong to the same batch as
that used by Kessel et al. (1987), and were tested chromato-
graphically by that group. Their chromatographic analysis
agreed with our own (Figure 4). Stock solutions of Hp, Pll,
TPPS3 and TPPS4 were made up in 0.03M NaOH + 0.15M
NaCl, whereas dimethyl sulphoxid (DMSO) was stock
solvent for Pp, Ppp, TPPS20 and TPPS2a.
All other chemicals used were of the highest purity
commercially available.
Fresh human plasma sampled in EDTA tubes was used in
all experiments and was obtained from the same healthy
person who had fasted overnight. All solutions for ultra-
centrifugation were made up with 0.1 M Tris-HCl buffer,
pH 7.35, containing 0.4mg EDTA (potassium salt) per ml.
Ultracentrifugation
A Beckman L8-70M ultracentrifuge with a fixed angle 70.1
Ti rotor was used. It was found that a 15 h run at
70,000 r.p.m. was suitable for a good separation of the
different protein fractions. A 74 h run at 32,000 r.p.m., using
a centrifuge with an SW-40 swinging bucket rotor, gave
similar results, the only significant difference being a slightly
better separation at the top of the gradient (i.e. in the
VLDL/LDL region). The high-speed/short time method was
used in this study, to reduce ultracentrifuge time and to
reduce possible ageing effects on the samples. Our gradient,
as well as those used by others (Chapman et al., 1981; Kelly
& Krusky, 1986), is slightly modified from that used by
Redgrave et al. (1975). The top fraction of the gradient was
made up using 0.15 M NaCl, but at higher densities we
employed CsCl instead of NaCl/KBr, as CsCl gives a lower
molarity of salt at a given density. This fact may be
Br. J. Cancer (1989), 59, 184-188PORPHYRINS IN HUMAN PLASMA PROTEINS 185
important for the separation since it is well known that an
increase in the salt concentration results in a decrease in
porphyrin solubility. Furthermore, for the same reason we
chose to apply the drug-containing plasma at the top of the
gradient instead of at d= 1.15-1.312gml-1 as employed by
other groups (Chapman et al., 1981; Nilsson et al., 1981;
Kelly & Krusky, 1986; Redgrave et al., 1975). Pure plasma
gives a similar protein distribution pattern whether it was
applied at the top or at the bottom of the gradient. Finally,
we chose to use a density of 1.35 gml- I at the bottom of the
tube (Figure 1), instead of 1.21, to prevent the heaviest
proteins and/or protein-porphyrin complexes from
precipitating at the bottom. Several gradients known from
the literature (Chapman et al., 1981; Kelly & Krusky, 1986;
Nilsson et al., 1981) were tested in a series of experiments
using the SW-40 rotor and found to give similar relative
separations as the gradient used by us. A separate paper,
giving the explicit experimental data on which our choice of
method is based, will be published later.
Concentration
The porphyrin binding patterns obtained here refer to
7pgml-1 plasma in the case of Pll and 144gml-P plasma
in the case of all other porphyrins. Reducing the plasma
concentration by a factor of 5 while keeping the total
porphyrin concentration constant (i.e. 35-70 pg porphyrin
per ml plasma equivalent to 2.5-5mg per kg bodyweight)
gave similar results as for 7-14pgml-1 for all substances
tested in this respect, i.e. Hp, Pll, Pp and TPPS4.
Analysis
Gradients are often analysed from the bottom up. It was
found that this method resulted in a contamination of the
HDL fraction by other heavy proteins and an apparatus was
therefore constructed which analysed and fractionated the
gradient from the top downwards. By means of a peristaltic
pump and an LKB 2098 Uvicord III monitor with
appropriate optical filters the absorbences (1 cm) at 276 nm
(proteins) and at 405 nm (porphyrins) were continuously
monitored. Fractions were also collected and measured
spectrophotometrically (Cary 118) since the tetraphenyl
porphine sulphonates have their absorption maximum at
417 nm in our solvent. From one sample to another the
position of the protein maxima in the gradient might change
slightly (i.e. by ± one fraction). However, with three
exceptions (see Results) the maxima of the porphyrin
distribution coincided exactly with the maxima of the protein
distribution in the same run.
HPLC
High performance liquid chromatography was carried out
with an RP18 column and a methanol/water gradient
buffered at pH7.4 as described previously (Sommer et al.,
1984).
Results
The initial gradient and that obtained after centrifugation
are shown in Figure 1. The protein distribution (A280nm), is
shown in the upper parts of Figures 2 and 3. LDL,
lipoprotein(a) (Lp(a)), HDL and heavy proteins (mostly
human serum albumin (HSA)) are well separated. The
separation is similar to the separations obtained by others by
the use of lower speeds and longer times of centrifugation,
except that in our high r.p.m. experiments VLDL is not
resolved from the LDL peak. Using the present gradient, but
lower centrifugation rates (SW-40 rotor) and longer times,
the VLDL was separated fropm the LDL peak (data not
shown). From such data it may be inferred that 5-15% of
the LDL-area in Figures 2 and 3 is due to VLDL. The
reproducibility from one run to another and between blood
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Figure I Outline of the gradient before (left) aind .lfter centrifu-
gation (15 h, 70,000r.p.m.). The classification of the lipoprotein is
according to Patch & Patch (1986).
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Figure 2 (a) Protein distribution in the gradient. Mean value
and standard errors from six individual samples. (b) Distribution
in the gradient of the following porphyrins: TPPS, (0), TPPS2a
(A), TPPS2. (V), TPPS3 ([l) and TPPS4 (x). Reproducibility
between separate runs better than 10% of the values shown (in
the LDL region, the errors are larger (20%) in the case of low
LDL binding).
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Figure 3 (a) Protein distribution in the gradient. (b) Distribu-
tion in the gradient of the following porphyrins: Pp (A), Hp (0)
and Ppp ([l). (c) Distribution of Pll in the gradient. Centrifuga-
tion: 15h, 70,000 r.p.m.
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Figure 4 (a) HPLC of a mixture of TPPS4, TPPS3, TPPS20,
TPPS2a and TPPS1 on a RP 18 column eluted with a water/
methanol gradient. The porphyrins were also run separately for
identification of the peaks. (b) Distribution of the same porphyr-
ins between LDL, HDL and heavy proteins (HSA on the figure).
The percentage bound to each fraction was determined by
weighing of distributions such as those shown in Figure 2.
LDL, fractions 1-11; HDL, fractions 11-23; HSA, fractions
23-32.
Table I Distribution of porphyrins among human plasma proteins
(centrifugation 15h, 15°C, 70,000r.p.m.)
Distribution (%)
HPLC ret. time
Porphyrin (min) on RP18 LDL HDL Heavy proteins
Ppp 9.5 9 57 34
Hp 3.6, 4.0 10 (6.5) 55 (38.4) 35 (55.1)
PII 3.6-20 16 70 14
Pp 18 22 (20) 41 (38) 37 (42)
TPPS4 0.05 1-2 (3) 18 (14) 80-81 (81)
TPPS3 0.35 6 (6) 68 (18) 26 (73)
TPPS2. 3.95 7 (17) 74 (43) 19 (38)
TPPS2a 10.1 36 (38) 55 (53) 9 (5)
TPPS1 20.0 30 (23) 60 (80) 10 (<2)
Data from Reyftman et al. (1984) for Hp and Pp and Kessel et al.
(1987) for the TPPS-series are included in parentheses for
comparison.
Reproducibility of percentages bound to the different proteins
better than 15% of the values shown, cf. legend of Figure 2.
samples taken on different days was good, consistent with
the s.e. bars shown on Figure 2.The maxima of the LDL,
Lp(a), HDL and HSA peaks were found at fractions 4-5,
11-13, 17-19 and 28-29, respectively (Figures 2 and 3). In
the cases of Hp, Pp, Ppp, PII, TPPS, TPPS1 and TPPS2a
(Figures 1 and 2), the maxima of the dye distribution always
coincide with the maxima of the protein peaks. However, in
the case of TPPS3 the 417nm peak in the HDL-region was
shifted by one fraction to the right compared to the 280 nm
peak and in the case of TPPS20 the 417 nm peak in the
HDL-region was shifted by three fractions to the right
compared to the 280 nm peak. The latter shift is seen in the
lower part of Figure 2. Furthermore, the major peak of the
TPPS4-adduct(s) is slightly shifted to the denser region of the
heavy proteins by about one fraction, as seen in Figure 2.
Integration over distributions, as shown in Figures 2 and 3
by weighing the areas under the curves between given
fractions (see legend to Figure 3), resulted in the data shown
in Table I. Thus, in the present work we have not attempted
to measure thermodynamic affinities but only the relative
distributions of the drugs between the plasma proteins. We
emphasise that the concentration of each plasma protein in
the samples has remained constant to within 5% throughout
the work. There may be a slightly different distribution of
aggregated and monomeric species among the different
serum proteins. However, absorbance measurements as
performed in the present work appear to give correct
distributions since fluorescence measurement was found to
give similar distributions (data not shown). (The fluorescence
quantum yields of porphyrins are very sensitive to the state
of aggregation.) The porphyrin amount bound to VLDL was
small compared to that bound to LDL (less than 15%) and
therefore these two fractions are taken together. Only Pp
and TPPS2a showed a tendency to bind to Lp(a). Even in
these two cases, the fraction of the porphyrins bound to
Lp(a) is small compared to that bound to HDL (< 5%) and
these two fractions are taken together in Table I.
When PII, Hp or Pp were incubated with plasma for
different times (0, 4 and 16h) at 370C their distributions
were almost identical to those shown in Figure 3.
Discussion
The relative binding of the porphyrins to LDL increases
generally, as expected, with increasing lipophilicity (Table I,
Figure 3). Thus, Pp is more extensively bound to LDL than
the structurally similar, but more polar Hp. Corre-
spondingly, the relative binding of the porphyrins to the
heavy proteins (mainly HSA) generally decreases with
increasing lipophilicity, as best illustrated by the TPPS-series
(Table I, Figure 3). However, there are important exceptions
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protein region in spite of the fact that the latter porphyrin is
significantly more polar than the former one. Similarly
TPPS2a binds more extensively to LDL than does TPPS1,
which is significantly less polar. This may be related to the
asymmetric charge distribution on TPPS2a, which may cause
a high affinity for a lipid/water interface. The asymmetry of
TPPS2a has been previously invoked by Kessel et al. (1987)
as an explanation for their observation that TPPS2a has a
higher uptake in cells than TPPS1. In summary, the relative
binding capacity LDL has for a drug is mainly related to the
lipophilicity of the drug, although other factors, such as
properties of different sidegroups and the asymmetry/
symmetry of the charge distribution play important roles for
this affinity.
For most of the drugs we have tested, where these can be
compared with results in the literature, there is generally
broad agreement (Table I). However, in the cases of Hp and
TPPS2 we find relatively less in the heavy fraction and in the
LDL fraction and more in the HLD fraction than did
Reyftman et al. (1984) and Kessel et al. (1987). The
discrepancy is even greater in the case of TPPS3, for which
we find much more in the HDL fraction and much less in
the heavy protein fraction than did Kessel et al. (1987). The
porphyrins which we find mainly in the heavier part of
HDL, i.e. in HDL3 (see Figure 1), seem in Kessel's
experiments to have been less well resolved from the albumin
peak than in our case. This may be related to an effect of
salt on the relative binding of TPPS3 as in his experiments
the porphyrin-labelled plasma was applied at a high KBr
concentration. Indeed, we have shown (unpublished results)
that, in the case of Hp, high salt causes more Hp to bind in
the heavy pattern region. The fact that TPPS3 and TPPS2o
seem to be bound more substantially to the heavier
subfraction of HDL than the other porphyrins tested should
be noted. These compounds are more polar than TPPS2a and
TPPS1, just as the heavier subfraction of HDL is more polar
than its lighter fraction. It is also noteworthy that the
TPPS4-peak at high densities seems to occur at a somewhat
higher density than the protein peak in that region, implying
that TPPS4 appears to be bound not only to albumin but
also to one or more of the other heavy proteins.
HpD injected in mice is reported to be lost much faster
from the LDL fraction than from the HDL fraction (Kessel,
1986), as is Hp injected in mice and rabbits (Barel et al.,
1986). Consequently, these observations would seem to
indicate that the binding and release of these drugs to the
lipoproteins is slow and that LDL is degraded faster than
HDL. The same group showed for systemic administration
of Hp to cancer patients that, although Hp is lost with
similar rates from LDL and HDL, it is lost at lower rates
from VLDL (Jori et al., 1984). However, from the present
results the distributions of PII as well as those of Hp and Pp
between the plasma proteins are similar for different
incubation times ranging from 0 to 4 h (PIT) and 0 to 16 h
(Hp and Pp) at 37°C (data not shown). Thus equilibrium
seems to be rapidly reached. Similarly, recent results
obtained by ultracentrifugation of sera from patients injected
with PII indicate that there is no change in the distribution
of the drug with time between injection and sampling
(Brown et al., work in progress), which is in agreement with
our present results of rapid establishment of equilibrium.
The possibility that there is a species difference in the
relative stability of circulating porphyrin-lipoprotein
complexes should be noted (but see below).
The assumption to be found in the literature that the
tumour localising ability of porphyrins used in PDT may be
related to their relative binding to LDL (Jori et al., 1984;
Reyftman et al., 1984; Barel et al., 1986; Kessel, 1986) is not
fully supported by the present work. Hp has a higher relative
affinity for LDL than TPPS4 and Pp has an even higher
affinity (Table I), but Hp and Pp are generally considered
inefficient tumour localisers. Pll has a relative affinity for
LDL lying between that of Hp and that of Pp but is a good
tumour localiser as reported by a number of authors (see the
review by Moan, 1986). Moreover, TPPS4 has a very low
affinity for LDL (see Table I) and a relatively high affinity
for heavy proteins, but is still one of the best tumour
localisers studied so far, with respect both to absolute
tumour uptake and to selectivity (Winkleman, 1985;
Evensen, 1985; Peng et al., 1987). According to Kessel et al.
(1987), albumin-bound drugs accumulate preferentially in
stromal elements in tumour tissue while lipoprotein-bound
drugs mediate intracellular localisation. As noted above,
TPPS4 appears to be bound not only to albumin but also to
other heavy proteins which may contribute to its distribution
in vivo.
The tumour selectivity of a drug may be related as much
to its retention in tumour tissue as to its initial deposition.
For this initial deposition, LDL transport may play an
important role. Thus, it has been shown that a lipophilic
fluorophore carried by LDL is selectively deposited in
endothelial cells in the vasculature (Netland et al., 1985).
Furthermore, strong PDT-effects on endothelial cells have
been reported (Chaudhuri et al., 1987). The difference in
retention of different porphyrins in cells is demonstrated by
our HPLC experiments, showing that washing of HpD-
loaded cells with a medium containing serum results in a
selective removal of the monomeric components Hp, Pp and
hydroxyethylvinyl deuteroporpohyrin (Moan & Sommer,
1983).
Quite apart from the actual mechanisms of the drug
uptake, there exists the possibility that the binding capacity
for a drug (rather than its lipophilicity) is a good index for
cellular uptake, as suggested by previous results for cellular
uptake of TPPS analogues (Kessel et al., 1987).
We are forced to conclude that at present the determinants
of tumour localisation of different drugs are poorly
understood. LDL-binding may play one role, heavy proteins
another. Other lipoproteins, such as VLDL, HDL (HDL2
and/or HDL3) and perhaps VHDL (very high density
lipoproteins) as well as other factors such as aggregation
properties, change in polarity with pH (Moan et al., 1980)
chemical nature of side groups or the presence of different
metal ligands (Hambright et al., 1975; Winkelman, 1967)
may also be important.
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